STAT+: Pharmalittle: We’re reading about a Lilly threat to 340B hospitals, Ebola vaccine funding, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and comfy breezes are greeting us. Who could ask for anything more? Actually, we could — it is time to reheat the kettle for another cuppa stimulation. Our choice today is old-fashioned green tea. And here is a helpful tip — a teaspoon of honey enhances the flavors splendidly. Of course, you are invited to join us. For the full experience, we are now hawking replicas — take a look. Meanwhile, here are a few tidbits to help you along. As always, do keep in touch. We appreciate feedback, criticism, and tips….
Eli Lilly has told about 50 hospitals participating in a federal drug discount program to submit comprehensive claims data over the next five days or they will no longer receive the mandated price breaks, STAT writes. The move comes after the company announced a policy last January demanding such data in a bid to reduce what it calls duplicate discounts paid to participating hospitals. For the past few years, more than 2,300 hospitals have complied with the demand, but Lilly said that some of the larger hospitals systems around the U.S. have refused to do so, despite recent follow-up letters regarding the policy that went into effect on Feb. 1. Up to 1,000 have so far not complied.
The U.S. Food and Drug Administration is scheduled to have a closed-door roundtable this week with over a dozen groups advocating for rare disease treatments, Bloomberg Law reports. The meeting, scheduled for Wednesday, will connect FDA Acting Commissioner Kyle Diamantas and other senior agency officials with at least 10 rare disease groups for a private conversation about advancing treatments that often struggle to meet the agency’s rigorous approval process. The meeting comes as the rare disease community has sought more clarity from regulators amid turmoil over recent decisions for rare drugs. Under former Commissioner Marty Makary, who resigned last month, several initial rejections were issued to companies seeking to market rare disease drugs and gene therapies.
Continue to STAT+ to read the full story…
المصدر: STAT News
